Holen Sie sich die Stockscreener-App
161.28
1.89%
2.99
Handel nachbörslich:
161.28
Schlusskurs vom Vortag:
$158.29
Offen:
$159.21
24-Stunden-Volumen:
723.32K
Relative Volume:
0.50
Marktkapitalisierung:
$11.17B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$302.80M
KGV:
37.54
EPS:
4.2965
Netto-Cashflow:
$387.80M
1W Leistung:
-1.95%
1M Leistung:
+7.01%
6M Leistung:
-44.20%
1J Leistung:
-45.77%
1-Tages-Spanne:
$158.30
$161.82
1-Wochen-Bereich:
$153.64
$164.40
52-Wochen-Spanne:
$138.79
$354.88
Insulet Corp Stock (PODD) Company Profile
Firmenname
Insulet Corp
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
161.28 | 11.17B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corp Aktie (PODD) Neueste Nachrichten
PODD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - GlobeNewswire Inc.
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
PODD Shareholder Alert: Insulet Corporation Securities - GlobeNewswire
Stifel cuts Insulet stock price target on valuation, keeps buy rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Insulet stock reflects steady diabetes tech demand as investors watch U.S. growth - AD HOC NEWS
Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47% - Yahoo Finance
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation LawsuitPODD - Morningstar
PODD Shareholder Alert: Insulet Corporation Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Business Wire
Insulet focuses on diabetes technology growth. Business model supports recurring revenue - Ad-hoc-news.de
Levi & Korsinsky Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 31, 2026PODD - Morningstar
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
PODD Maintained by Citigroup -- Price Target Raised to $172 - GuruFocus
Insulet (PODD) Launches Omnipod 5 In Spain, Is The Upside Already Priced In? - simplywall.st
Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut? - Yahoo Finance
Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain - Yahoo Finance
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit - PR Newswire
Form 4 Insulet Corporation For: 7 July By Investing.com - Investing.com Nigeria
Insulet Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Insulet (PODD) director updates award to 151 deferred stock units - Stock Titan
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now? - Yahoo Finance
Why Insulet (PODD) Could Beat Earnings Estimates Again - Yahoo Finance
Insulet launches Omnipod 5 in Spain - MedTech Dive
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
PODD DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Insulet Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - Morningstar
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target - Insider Monkey
FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports - Benzinga
Class action lawsuit filed against Insulet over alleged false statements causing investor losses - Pluang
INSULET CORPORATION (PODD) INVESTOR ALERT Investors With - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm - Barchart.com
Insulet Misled Investors on Manufacturing Procedures, Suit Says - Bloomberg Law News
PODD Expands Omnipod 5 Launch to Spain, Enhancing Diabetes Care - GuruFocus
Insulet launches Omnipod 5 insulin system in Spain - Investing.com
Insulet launches Omnipod 5 insulin system in Spain By Investing.com - Investing.com South Africa
Insulet brings tubeless diabetes tech to Spain with Omnipod 5 launch - Stock Titan
VERI DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Veritone, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
PODDInsulet Corp Latest SEC Filings - Finviz
Rosen Law Firm Urges Insulet Corporation (NASDAQ: PODD) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Class action lawsuit filed against Insulet over alleged false statements on product safety. - Pluang
Bernstein SocGen cuts Insulet stock price target on valuation concerns - Investing.com
Insulet faces shareholder lawsuit over alleged false safety claims and product issues. - Pluang
Class action filed against Insulet over alleged product safety and disclosure issues, stock drops follow. - Pluang
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation - GlobeNewswire
Grabar Law Office Investigates Claims on Behalf of Shareholders of Insulet Corporation (PODD) - TMX Newsfile
FDA Alerts on Insulet (PODD) Device Safety Concerns - GuruFocus
Insulet (PODD) Faces Class I Recall of Omnipod Insulin Pump Syst - GuruFocus
Insulet Corporation: A High-Quality Growth Story Trading At A Reasonable PEG - Seeking Alpha
Class action lawsuit filed against Insulet over defective insulin delivery systems and stock drops. - Pluang
Finanzdaten der Insulet Corp-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):